TOULOUSE, France & LAKELAND, Mich.–(BUSINESS WIRE)–Regulatory News: Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular, metabolic diseases, and new HDL-based vectors for the targeted drug delivery in the oncology field announces today the […]